New Zealand markets close in 1 hour 26 minutes
  • NZX 50

    12,070.55
    +102.83 (+0.86%)
     
  • NZD/USD

    0.6425
    -0.0007 (-0.11%)
     
  • NZD/EUR

    0.5915
    +0.0004 (+0.08%)
     
  • ALL ORDS

    7,718.00
    +31.90 (+0.42%)
     
  • ASX 200

    7,507.50
    +30.80 (+0.41%)
     
  • OIL

    79.06
    +0.19 (+0.24%)
     
  • GOLD

    1,940.80
    -4.50 (-0.23%)
     
  • NASDAQ

    12,101.93
    +189.54 (+1.59%)
     
  • FTSE

    7,771.70
    -13.17 (-0.17%)
     
  • Dow Jones

    34,086.04
    +368.95 (+1.09%)
     
  • DAX

    15,128.27
    +2.19 (+0.01%)
     
  • Hang Seng

    21,740.27
    -102.06 (-0.47%)
     
  • NIKKEI 225

    27,385.08
    +57.97 (+0.21%)
     
  • NZD/JPY

    83.5320
    -0.0900 (-0.11%)
     

Agios to Participate in December Investor Conference

Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022, at 11:25 a.m. ET.

A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Investor and Media Contact:
Jessica Rennekamp, 857-209-3286
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com